Article
Real-World Outcomes of Direct-Acting Antiviral Treatment and Retreatment in United Kingdom-Based Patients Infected With Hepatitis C Virus Genotypes/Subtypes Endemic in Africa.
The Journal of infectious diseases - 21 Sept 2022
Aranday-Cortes Elihu, McClure C Patrick, Davis Christopher, Irving William L, Adeboyejo Kazeem, Tong Lily, da Silva Filipe Ana, Sreenu Vattipally, Agarwal Kosh, Mutimer David, Stone Benjamin, Cramp Matthew E, Thomson Emma C, Ball Jonathan K, McLauchlan John
Abstract excerpt
BACKGROUND: Chronic hepatitis C virus (HCV) infection affects 71 million individuals, mostly residing in low- and middle-income countries (LMICs). Direct-acting antivirals (DAAs) give high rates of sustained virological response (SVR) in high-income countries where a restricted range of HCV genotypes/subtypes circulate. METHODS: We studied United Kingdom-resident patients born in Africa to examine DAA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.